Glucosamine and chondroitin sulphate in the treatment of arthritis;Glukosamin og kondroitinsulfat ved behandling af slidgigt

Ugeskrift for Laeger

Volumn 165, Issue 5, 2003, Pages 451-454

  Angermann, Peter ^a  

^a Gildhoj Speciallægeklinik ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE; PLACEBO;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; DENMARK; DRUG ACTIVITY; DRUG EFFECT; HUMAN; LONG TERM CARE; META ANALYSIS; REVIEW; SIDE EFFECT;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS; CHONDROITIN SULFATES; EVIDENCE-BASED MEDICINE; GLUCOSAMINE; HUMANS;

EID: 0037467915     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Towheed TE, Anastassiades TP, Shea B, Houpt J. Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis (Cochrane review). I: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
2. McAlindon TE, LaValley MR, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis. JAMA 2000; 283: 1469-75.
3. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-11.
4. Mazieres B, Combe B, Phan Van A, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol 2001; 28: 173-81.
5. Reginster JY. Deroisy R. Rovati LC, Lee RL, Lejeune E, Bruyere O et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
6. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. Rheum Dis N Am 1999; 25: 379-95.
7. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. Arzneim Forsch 2001; 51: 699-725.
8. De los Reyes GC, Koda RT, Lien EJ. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey. Prog Drug Res 2000; 55: 83-103.
9. Delafuente JC. Glucosamine in the treatment of osteoarthritis. Rheum Dis Clin N Am 2000; 26: 1-11.
10. Kim JJ, Conrad HE. Effect of D-glucosamine concentration on the kinetics of mucopolysaccharide biosynthesis in cultured chick embryo vertebral cartilage. J Biol Chem 1974; 249: 3091-7.
11. Vidal y Plana RR, Karzel K. Glukosamin. Seine Bedeutung für den Knorpelstoffwechsel der Gelenke. 1: Biochemie der Proteoglykane, Untersuchungen an in vitro-kulturen Embryonaler Mäuse -Fibroblasten und Knochenanlangen. Fortsch Med 1980; 98: 557-62.
12. Raiss R. Einfluss von D-Glucosaminsulfat auf experimentell geschädigten Gelenkknorpel. Fortschr Med 1985; 103: 658-62.
13. Bassleer C, Henrotin Y, Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J. Tiss Reac 1992; 14: 231-41.
14. Bassleer C. Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartil 1998: 6: 427-34.
15. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998; 335: 59-66.
16. Hungerford DS. Treating osteoarthritis with chondroprotective agents. Orthopedics Special Edition 1998; 4: 39-42.
17. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneim Forsch 1991; 41: 542-5.
18. Setnikar I, Cereda R, Pacini MA, Revel L. Antireactive properties of glucosamine sulfate. Arzneim Forsch 1991; 41: 157-61.
19. Rovati LC. Clinical research in osteoarthritis: design and results of short-term and long-term trials with disease-modifying drugs. Int J Tissue Reac 1992; 14: 243-51.
20. Piperno M, Reboul P, le Graverand M-PH, Peschard M, Annefeld M, Richard Met al. Osteoarthritic cartilage fibrillation is associated with a decrease in chondrocyte adhesion to fibronectin. Osteoarthritis Cartil 1998; 6: 393-9.
21. Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartil 1994; 2: 61-9.
22. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneim Forsch 1998; 48: 469-74.
23. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 110-4.
24. Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartil 1994; 2: 51-9.
25. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-30.
26. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneim Forsch 1986; 36: 729-35.
27. Setnikar I, Palumbo R, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneim Forsch 1993; 43: 1109-13.
28. Reichelt A, Förster KK, Fischer M, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthrosis of the knee. Arzneim-Forsch 1994; 44: 75-80.
29. Baron AD, Zhu J-S, Zhu J-H, Weldon H, Maianu L, Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. J Clin Invest 1995; 96: 2792-2801.
30. Hardingham T Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998; 6 (suppl A): 3-5.
31. Baici A Hörler D, Moser B, Hofer HO, Fehr K, Wagenhäuser FJ. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992; 12: 81-8.
32. Paroli E, Antonilli L, Biffoni M. A pharmacological approach to glycosaminoglycans. Drugs Exptl Clin Res 1991; 17:9-20.
33. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoar thrifts, J Rheum 1996; 23: 1385-91.
34. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 (suppl A): 14-21.
35. Uebelhart D, Thonar EJ-MA Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage 1998; 6 (suppl A): 6-13.
36. Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 2000; 381: 229-40.
37. Beren J, Hill SL, Diener-West M, Rose NR. Effect of pre-loading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on arthritis in rats. Exp Biol Med 2001; 226: 144-51.
38. Andermann G, Dietz M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: Chondroitin; sulphate (CSA). Eur J Metab Pharmacokin 1982; 7: 11-6.
39. Conte A, de Bernardi M, Palmieri L, Luardi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneim Forsch 1991; 41: 768-72.
40. Bourgeois P, Chales G, Dehais J, Delchambre B, Kuntz J-L, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3x400 mg/day vs placebo. Osteoarthritis Cartil 1998; 6: 25-30.